Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
Oculis Holding AG announced favorable pre-IND feedback from the FDA supporting the clinical development pathway for Privosegtor, a novel neuroprotective candidate, in treating acute multiple sclerosis (MS) relapses. The FDA confirmed that existing data can be leveraged for the IND submission planned for Q4 2026, accelerating Oculis's expansion of P…